Compare CNTN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTN | NYXH |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5M | 137.5M |
| IPO Year | 2021 | 2021 |
| Metric | CNTN | NYXH |
|---|---|---|
| Price | $1.88 | $0.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | ★ 735.7K | 217.2K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.10 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $275.91 |
| Revenue Next Year | N/A | $93.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $0.80 |
| 52 Week High | $5.27 | $5.92 |
| Indicator | CNTN | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 23.47 |
| Support Level | $1.75 | N/A |
| Resistance Level | $2.40 | $1.69 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 27.07 | 5.85 |
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.